Patient guide
Compounded and FDA-approved medicines: understand the distinction
The ingredient name alone does not tell you a product’s approval status, formulation, or evidence.
Document research · No independent medical review claimedOn this page
Semaglutide or tirzepatide can appear in an advertisement without telling you everything about the finished product. The manufacturer, formulation, route, and regulatory status still matter. Those details should be clear before a price comparison becomes a treatment decision.
Compounding can meet a patient-specific medical need in appropriate circumstances. Compounded drugs, however, are not FDA-approved. FDA has not reviewed each such finished preparation for safety, effectiveness, and quality before marketing.
Find the product, not just the ingredient
Request the preparation’s full name, route, ingredients, concentration where relevant, and dispensing pharmacy. A vial, tablet, lozenge, and product used under the tongue should not be treated as interchangeable simply because an ingredient overlaps. The clinician should explain why the proposed formulation is appropriate and what evidence actually concerns it.
Read facility descriptions carefully
A facility’s registration, regulatory category, or reference to standards does not confer FDA approval on every medicine it prepares. Likewise, a pharmacy partnership is not a clinical endorsement of a review site. Verify the pharmacy assigned to the individual order and its applicable licensing information separately from the product’s approval status.
Keep current availability and policy separate
Compounding policy can depend on the medicine, circumstances, and current FDA guidance. A historical shortage or an old article does not establish that a particular offer is permitted now. Consult the current FDA material and ask the prescribing professional why an available approved treatment would or would not meet the patient’s medical needs.
Recognize what a review cannot establish
Our reviews describe accessible documents and leave unanswered questions visible. They do not test a vial, verify every ingredient batch, or determine an individual patient’s treatment. If an advertisement uses strong claims about equivalence or superior results, ask for evidence for the actual preparation. The pharmacy checklist helps organize the identity questions that accompany that discussion.
Trace the information
Sources & research notes
Provider documents describe the provider’s own offer. Official medical references explain context; they do not endorse this publication or its featured partner.
- FDA: risks of compounded drugs Regulatory / public agency · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs Regulatory / public agency · Checked September 22, 2026
- FDA: current GLP-1 compounding policy Regulatory / public agency · Checked September 22, 2026
- FDA: compounded semaglutide dosing errors Regulatory / public agency · Checked September 22, 2026
Use this guide to prepare questions, not to choose or change a prescription without clinical advice. Research method · Commercial disclosure